Physician profile
Benjamin Sadoff
NPI 1720003163
$827.55
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $724 · 2020: $103.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $193.65 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $167.91 | 2019 | |
| Daiichi Sankyo INC. | $93.13 | 2019 | |
| Merck Sharp & Dohme LLC | $70.07 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.52 | 2019 | |
| Novo Nordisk INC | $51.54 | 2019 | |
| Vivus LLC | $46.86 | 2019-2020 | |
| Genentech USA, INC. | $38.97 | 2019 | |
| Lilly USA, LLC | $31.00 | 2019 | |
| Boston Scientific Corporation | $28.46 | 2019 | |
| Shionogi INC | $15.67 | 2019 | |
| Therapeuticsmd, INC. | $11.91 | 2019 | |
| Astellas Pharma US INC | $10.86 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Sadoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.